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Objectives: To determine the effect of chondroitin sulfate (CS) on inﬂammatory mediators and proteolytic
enzymes induced by interleukin-1b (IL-1b) and related to cartilage catabolism in murine osteoblasts.
Design: Osteoblasts were obtained by enzymatic digestion of calvaria from Swiss mice and cultured for
3 weeks as a primary culture. Cells were then stimulated with IL-1b (1 or 10 ng/ml). CS-treated osteo-
blasts were incubated with 100 mg/ml of CS during the last week of culture w/o IL-1b for the last 24 h.
Expressions of cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1), 15-PG
dehydrogenase (15-PGDH), matrix metalloproteinases-3 and -13 (MMP-3 and -13), osteoprotegerin
(OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) were determined by real-time
polymerase chain reaction (PCR). PGE2, MMP-3 and MMP-13 release were assessed in the medium by
enzyme-linked immunosorbent assay or western-blotting.
Results: IL-1b increased COX-2, mPGES-1, MMP-3, MMP-13, RANKL expressions, decreased 15-PGDH
expression, and increased PGE2, MMP-3 and MMP-13 release. Interestingly, 7 days of CS treatment
signiﬁcantly counteracted IL-1b-induced expression of COX-2 (62%, P< 0.001), mPGES-1 (63%,
P< 0.001), MMP-3 (39%, P¼ 0.08), MMP-13 (60%, P< 0.001) and RANKL (84%, P< 0.001). Accord-
ingly, IL-1b-induced PGE2, MMP-3 and MMP-13 releases were inhibited by 86% (P< 0.001),
58%(P< 0.001) and 38% (P< 0.01) respectively.
Conclusions: In conclusion, our data demonstrate that, in an inﬂammatory context, CS inhibits the
production of PGE2 and MMPs. Since CS has previously been shown to counteract the production of these
mediators in chondrocytes, we speculate that the beneﬁcial effect of CS in Osteoarthritis (OA) could not
only be due to its action on cartilage but also on subchondral bone.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is not only characterized by articular carti-
lage destruction but also by an abnormal bone remodeling illus-
trated by subchondral bone sclerosis and varying degrees of
osteophyte formation1. OA subchondral bone is the site of several
dynamic morphological changes involving a remodeling process
associated with an altered metabolism of osteoblasts2. A growingF. Berenbaum, UR 4, Univer-
ing, Stress and Inﬂammation
rance. Tel: 33-144-27-22-83;
Berenbaum).
ly to this work.
s Research Society International. Pnumber of studies indicates that osteoblasts could partake in the
disease process by releasing mediators involved in articular carti-
lage degradation2. Therefore, therapies that interfere with bone
remodeling could possibly block or at least attenuate the progres-
sion of cartilage alterations.
Inﬂammation is a crucial component of the initiation and the
evolution of OA3. Cartilage degradation in OA is due in part to an
increased release of inﬂammatory mediators, such as interleukin-1
(IL-1b) and prostaglandin (PG) E24. PGs are also considered as
critical local factors that modulate bone remodeling through their
effects on both osteoblasts and osteoclasts and have been linked to
many bone diseases5. PGE2 is the most prominent eicosanoid in
bone tissue, mainly produced by osteoblasts which release it upon
different stimulations and also respond to external PGE26.ublished by Elsevier Ltd. All rights reserved.
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tion depends on the coordinated activities of cyclooxygenase-2
(COX-2) and microsomal PGE synthase 1 (mPGES-1). Collagen-
induced arthritis is signiﬁcantly less severe in mice lacking
mPGES-1 than in control mice7 indicating that PGE2 plays a pivotal
role in inﬂammatory joint disease. The synthesis of mPGES-1 by
chondrocytes from OA patients is also increased by IL-1b8. The
coordinate induction of COX-2 and mPGES-1 is essential for PGE2
production by osteoblasts treated by inﬂammatory stimulants.
In vivo, PGE2 is rapidly converted to an inactive metabolite by
15-hydroxyePG dehydrogenase (15-PGDH)9. Synthesis of 15-PGDH
is abnormal in various diseases9. We recently reported that
15-PGDH was synthesized by mouse chondrocytes and osteo-
blasts10,11. However its synthesis and regulation in bone tissue has
not been characterized yet.
Matrix metalloproteinase (MMP) is a family of proteolytic
enzymes involved in the degradation of the extracellular matrix of
various tissues including bone. More than 20 different mammalian
MMPs have been identiﬁed, and many physiological roles have
been reported12. MMPs are involved in bone resorption and matrix
degradation13,14. We have recently reported that murine osteo-
blasts produce MMP-3 and MMP-1311.
Abnormal levels of two factors that play a major role in bone
resorption, the receptor activator of nuclear factor-kappa B ligand
(RANKL) and osteoprotegerin (OPG), have been found in human OA
subchondral bone osteoblasts15. RANKL, a member of the tumor
necrosis factor (TNF) family, is an essential cytokine for osteoclast
differentiation and bone loss and acts as a survival factor for oste-
oclast precursors. OPG belongs to the family of TNF receptor16 and
is considered as a decoy receptor which inhibits the binding of
RANKL to its membrane receptor RANK. OPG is able to inhibit the
terminal stage of osteoclastic differentiation and to suppress its
activation as well as inducing the apoptosis of mature osteoclasts17.
This molecular triad OPGeRANKLeRANK is involved in the
orchestration of pathophysiological bone remodeling.
Chondroitin sulfate (CS) is a major component of the extracel-
lular matrix of many connective tissues. CS belongs to the family of
glycosaminoglycans (GAG), long unbranched polysaccharides con-
sisting of a repeating disaccharide unit which is often modiﬁed by
sulfation, acetylation or epimerization18. CS is widely distributed in
matrix where it forms an essential component of proteoglycans by
covalent links with proteins19. Commonly referred as a “symptom-
atic slow-acting drug in OA” (SySADOA), CS is widely used in the
management of OA patients20. In vitro, CS has been shown to have
anti-inﬂammatory and anti-catabolic properties on chondrocytes
(For review21) but little is known about its action on bone. In bone,
CS and other GAG are actively synthesized by osteoblasts and are
localized in the membrane of osteoblasts and in the extracellular
matrix22,23. In osteoblasts, CS inhibits the osteoblast-mediated
activation of osteoclasts by upregulating the expression ratio of
OPG/RANKL24,25. However, the molecular mechanisms on howGAG
mediates these effects in osteoblasts are not yet understood.
The aim of the present study was to investigate the effect of CS
on inﬂammatory mediators and proteolytic enzymes induced by
IL-1b and related to cartilage catabolism in murine osteoblasts.
Altogether, our data suggest that CS inhibits the synthesis of
proinﬂammatory and prodegradative mediators known to exert
deleterious effect at the bone-cartilage interface.
Materials and methods
Materials
All reagents were purchased from SigmaeAldrich (Lyon,
France), unless stated otherwise. Fetal calf serum (FCS) wasobtained from Invitrogen (Cergy-Pontoise, France). Collagenase A,
trypsin, hyaluronidase, collagenase D and complete protease
inhibitor mixture were from Roche Diagnostics (Meylan, France).
The enhanced chemiluminescence (ECL) Western-blot analysis
system was purchased from Amersham Pharmacia Biotech (Orsay,
France). The Immunoblot polyvinylidene diﬂuoride (PVDF)
membranes for western-blotting and kaleidoscope prestained
standards were obtained from Bio-Rad (Marnes-la-coquette,
France). Recombinant human IL-1bwas from PeproTech (Tebu-bio).
CS (avian CS, average MW 18 kDa, less than 1.5% protein contami-
nant) was from Pierre Fabre Laboratories, France.Primary calvaria mouse osteoblasts isolation and culture
Osteoblasts isolation and culture were performed as described
previously11. On day 15, osteoblasts were incubated with 10% FCS-
containing medium with CS (100 mg/ml) and medium changes
were done every 2e3 days. On day 20, IL-1b (1 or 10 ng/ml) was
added during 24 h. For acute phase stimulation, CS was not pre-
incubated at day 15 but added on day 20 in the same time as
IL-1b (same protocol using indomethacin at 10 mg/ml instead of CS).
The osteoblasts were then isolated from the extracellular matrix by
an enzymatic digestion with collagenase D (3 mg/ml, 30 min at
37C under agitation). After centrifugation, osteoblasts were kept
at 80C until ribonucleic acid (RNA) extraction. Cell viability was
assessed by trypan blue exclusion test. Osteoblast differentiation
and mineralization were tested by staining of alkaline phosphatase
and alizarin red respectively. These two parameters were not
modiﬁed by CS (data not shown). All experiments were performed
in duplicate or triplicate, 3 or 4 times with different calvaria oste-
oblasts populations.RNA extraction, reverse transcription, and real-time quantitative
reverse transcriptionepolymerase chain reaction (RT-PCR)
Total RNA was extracted from chondrocytes using the RNeasy
kit (Qiagen, Hilden, Germany), and concentrations determined
spectrophotometrically. Reverse transcription was performed on
1 mg total RNA, using the OmniScript RT kit (Qiagen). Messenger
RNA (mRNA) for HPRT, COX-2, mPGES-1, 15-PGDH, MMP-3, MMP-
13, OPG and RANKL were quantiﬁed using the Light Cycler LC480
(Roche Diagnostics) as described26. Speciﬁc primers for comple-
mentary DNA (cDNA) were chosen with the LightCycler Probe
Design 2 program based on mouse sequence information
(Table I).Proteins extraction and western-blotting
Protein from supernatant and immunoblot were prepared as
previously described8 with anti-human MMP-13 polyclonal Ab
(from Santa Cruz Biotechnology, Tebu-Bio). Signals were detected
by ECL and exposed to Fujiﬁlm LAS-300 (Fujiﬁlm Medical Systems,
Stamford, CT). For densitometry analysis, we used Image-Gauge
software (Science Lab 2004; Fujiﬁlm).Immunoassays for MMP-3 and PGE2
MMP-3 and PGE2 were directly measured in conditioned culture
media by speciﬁc enzyme immunoassays (EIAs) (Biosource Europe
and Cayman Chemical). The limit of detection of these immuno-
assays was 312 pg/ml for MMP-3 and 9 pg/ml for PGE2. The MMP-3
and PGE2 concentrations were analyzed at serial dilutions in
duplicate and were read against standard curves.
Table I
Sequences of mouse primers for the quantitative RT-PCR experiments
mRNA gene Sense (50-30) Anti-sense (50-30)
HPRT AGG-ACC-TCT-CGA-AGT-GT ATT-CAA-ATC-CCT-GAA-GTA-CTC-AT
COX-2 GCA-CCA-ATC-TGA-TGT-TTG-CAT-TC-3 GGT-CCT-CGT-TCA-AAA-TCT-GTC-TTG
mPGES-1 CTG-CTG-GTC-ATC-AAG-ATG-TAC-G CCC-AGG-TAG-GCC-ACG-GTG-TGT
15-PGDH GCC-AAG-GTA-GCA-TTG-GTG-GAT CTT-CCG-AAA-TGG-TCT-TGG-GGT-CT
MMP-3 TAC-GGG-TCT-CCC-CCA-GTT-TC GGT-TCG-GGA-GGC-ACA-GAT-T
MMP-13 TTC-TTC-TGG-CGG-CTG-CAT GGA-AGT-TCT-GGC-CCA-AAC-G
OPG ATC-AGA-GCC-TCA-TCA-CCT-T CTT-AGG-TCC-AAC-TAC-AGA-GGA-AC
RANKL TTT-CGT-GCT-CCC-TCC-TTT GCT-TCT-ATT-ACC-TGT-ACG-CCA
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All data were expressed as means with 95% conﬁdence interval
(CI). All experiments were repeated at least three times. Statistical
analyses were performed by Welch’s corrected t-test to compare
the mean values for two groups, and with one-way analysis of
variance with Bonferroni post hoc test to compare mean values
among >2 groups, using GraphPad Prism version (GraphPad Soft-
ware, San Diego, California, USA). P values of 0.05 or less were
considered signiﬁcant.
Results
Effects of CS on the release of PGE2 in IL-1b-stimulated mouse
osteoblasts
Since PGE2 is a pivotal catabolic mediator in OA, we tested the
effect of CS on PGE2 synthesis by mouse osteoblasts. We quantiﬁed
PGE2 production into the conditioned media after CS and/or IL-1b
treatment (Fig. 1). CS had no effect on the basal PGE2 release (Fig. 1).Fig. 1. Effect of CS on PGE2 release. Osteoblasts were treated for 7 days (A) or 24 h (B) in
indomethacin (10 mg/ml) (C). IL-1b (1 or 10 ng/ml) was added for the latest 24 h. The amoun
(EIA). PGE2 release are the mean with 95% CI of four independent experiments with two wAs expected, a 24 h incubationwith IL-1b at 1 or 10 ng/ml increased
the basal level of PGE2 release by 23- and 184-fold, respectively
[P< 0.001] [Fig. 1(A)]. When CS (100 mg/ml) was pre-incubated for
7 days before IL-1b treatment, the effect of IL-1b at 10 ng/ml on PGE2
productionwas decreased by 86% of inhibition [P< 0.001] [Fig.1(A)].
When the period of pretreatment was reduced from 7 days to 24 h
and CS incubated for 24 h with IL-1b, the level of PGE2 production
was not modiﬁed compared to osteoblasts stimulated by IL-1b alone
[Fig. 1(B)]. In order to compare the effect of CS with a nonsteroidal
anti-inﬂammatory drug (NSAID) in that particular condition, we
treated the mouse osteoblasts by indomethacin at 10 mg/ml for 24 h
w/o IL-1b. As expected, the level of IL-1b-induced PGE2 was
completely abolished by indomethacin [P< 0.001] [Fig. 1(C)].
CS inhibited the expression of COX-2 and mPGES-1 mRNA
and increased the expression of 15-PGDH in IL-1b-stimulated
mouse osteoblasts
We subsequently focused our study on the inducible enzymes
involved in PGE2 synthesis, COX-2 and mPGES-1. In addition, wethe presence or absence of CS (100 mg/ml) or for 24 h in the presence or absence of
t of the PGE2 release into the media (pg/ml) was measured by enzymatic immunoassay
ells/condition, analyzed in duplicate (corrected P-values: ***P< 0.001).
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PGE2. Osteoblasts were treated for 7 days with CS at 100 mg/ml and
with IL-1b for the latest 24 h. To determine the effect of CS on the
steady-state mRNA levels of various enzymes involved in PGE2
metabolism (COX-2, mPGES-1 and 15-PGDH), the cells were lysed
and the RNA were extracted (Fig. 2). As expected, RT-PCR revealed
that IL-1b at 1 and 10 ng/ml for 24 h increased synthesis of
COX-2 mRNA by 4.7-fold [P< 0.01] and 10.8-fold, respectively
[P< 0.001] [Fig. 2(A)] and mPGES-1 mRNA by 2.3-fold [P¼ 0.09]
and 7.8-fold, respectively [P< 0.001] [Fig. 2(B)]. 15-PGDH mRNA
expression was dramatically reduced by IL-1b at 1 and 10 ng/ml
(70% and 90% of inhibition respectively; [all P< 0.001]) [Fig. 2(C)].
Then, we examined whether CS could modulate the expression of
these three enzymes induced by IL-1b. CS did not signiﬁcantly alter
the mRNA basal levels of these three genes. However, the IL-1b-
induced COX-2 and mPGES-1 mRNA amounts were decreased
by a 7-days pretreatment with CS. Indeed, CS decreased the up-
regulation of COX-2 and mPGES-1 mRNA levels induced by 24 h
incubation with IL-1b at 10 ng/ml (62% of inhibition for COX-2
[P< 0.001] [Fig. 2(A)] and 63% of inhibition for mPGES-1
[P< 0.001] [Fig. 2(B)]). 15-PGDH mRNA amounts induced by a 24-
h incubation with IL-1b at 10 ng/ml were found to be not modu-
lated by treatment of cells with CS [Fig. 2(C)].
CS decreased IL-1b stimulated MMP-3 gene expression and protein
secretion in mouse osteoblasts
Since the matrix breakdown that occurs in OA is mainly due to
MMPs (especially MMP-3 and MMP-13), we assessed the inﬂuenceFig. 2. Effect of CS on IL-1b-induced pro-inﬂammatory gene expression. Osteoblasts were tr
added for the latest 24 h. Total RNAwas extracted and used in quantitative PCR to determine
for COX-2, mPGES-1, 15-PGDH and HPRT were generated by serial dilution of a cDNA mixt
amount of HPRT mRNA measured in the same cDNA. Values are the mean with 95% of four
and ***P< 0.001).of CS on the synthesis of these enzymes by osteoblasts. After 7 days
treatment with CS at 100 mg/ml and with IL-1b (1 or 10 ng/ml) for
the latest 24 h, CS did not signiﬁcantly alter the basal level of MMP-
3 mRNA. Moreover, as expected, stimulation with IL-1b at 1 ng/ml
or 10 ng/ml for 24 h, elevated this basal level of MMP-3 gene
expression in mouse osteoblasts by 170- and 180-fold, respectively
[P< 0.001] [Fig. 3(A)]. However, when CS was pre-incubated for
7 days before the IL-1b treatment at 10 ng/ml, IL-1b-induced-MMP-
3 gene expression decreases by 39% of inhibition [P¼ 0.08]
[Fig. 3(A)].
Using enzyme-linked immunosorbent assay (ELISA), we deter-
mined the effects of CS on MMP-3 release by measuring the protein
concentration in the media from osteoblasts. IL-1b stimulation at 1
or 10 ng/ml during 24 h leads to an 88-fold and 101-fold increase of
MMP-3 release in the media, respectively [P< 0.001] [Fig. 3(B)].
However, when CS was pre-incubated for 7 days before IL-1b
treatment at 10 ng/ml, IL-1b stimulated MMP-3 production was
decreased by 58% of inhibition [P< 0.001] [Fig. 3(B)].
CS inhibited MMP-13 gene expression and secretion following
IL-1b stimulation in mouse osteoblasts
Osteoblasts were treated during 7 days with CS (100 mg/ml) and
with IL-1b (1 or 10 ng/ml) for the latest 24 h. CS did not signiﬁcantly
alter the basal levels of MMP-13. Moreover, as expected, stimula-
tion with IL-1b at 1 or 10 ng/ml for 24 h, elevated this basal level of
MMP-13 gene expression by 9.32- and 17.46-fold, respectively
[P< 0.001] [Fig. 4(A)]. However, pretreatment with CS for 7 days
before the IL-1b treatment at 10 ng/ml, decreased the up-regulationeated for 7 days in the presence or absence of CS (100 mg/ml). IL-1b (1 or 10 ng/ml) was
steady-state mRNA levels of COX-2 (A), mPGES-1 (B), and 15-PGDH (C). Standard curves
ure. The amount of COX-2, mPGES-1 and 15-PGDH mRNA was normalized against the
independent experiments with n¼ 1/group/experiment (corrected P-values: **P¼ 0.08
Fig. 3. Effect of CS on IL-1b-induced MMP-3 mRNA expression and protein release.
Osteoblasts were treated for 7 days in the presence or absence of CS (100 mg/ml). IL-1b
(1 or 10 ng/ml) was added for the latest 24 h. Total RNA was extracted and used in
quantitative PCR to determine steady-state mRNA levels of MMP-3 (A). Media from
cells incubated were assayed for analyzing MMP-3 release into the media (B). The
amount of MMP-3 released into the medium (ng/ml) in response to IL-1b was
measured by ELISA. Values are the mean with 95% CI of four independent experiments
with n¼ 1/group/experiment, analyzed in duplicate (corrected P-values: ***P< 0.001).
Fig. 4. Effect of CS on IL-1b-induced MMP-13 mRNA expression and protein release.
Osteoblasts were treated for 7 days in the presence or absence of CS (100 mg/ml). IL-1b
(1 or 10 ng/ml) was added for the latest 24 h. Total RNA was extracted and used in
quantitative PCR to determine steady-state mRNA levels of MMP-13 (A). Media from
cells incubated were assayed for analyzing MMP-13 release into the media (B). Values
are the mean with 95% CI of four independent experiments with n¼ 1/group/experi-
ment, analyzed in duplicate. MMP-13 protein secretion into the medium in response to
IL-1b were assessed by immunoblotting. Blots in B are representative of three inde-
pendent experiments. The densitometric analyses of western-blot is the mean with
95% CI of three independent experiments [corrected P-values: **P¼ 0.076 for (IL-1
1 ng/ml), **P¼ 0.063 for (IL-1 10 ng/ml), and ***P< 0.001].
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of inhibition [P< 0.001] [Fig. 4(A)].
Using immunoblotting, we determined the effects of CS on
MMP-13 release by osteoblasts by measuring the expression of this
protein in the media. The analysis by densitometry of western-blot
shows that IL-1b stimulation at 1 or 10 ng/ml for 24 h, elevated the
level of MMP-13 release in the media by 13.12- and 13.94-fold,
respectively [P< 0.001] [Fig. 4(B)]. However, upon addition of CS for
7 days before IL-1b treatment at 10 ng/ml, IL-1b stimulated MMP-
13 production was decreased by 38% of inhibition [P< 0.01]
[Fig. 4(B)].
CS increased OPG and inhibited RANKL gene expression following
IL-1b stimulation in mouse osteoblasts
Osteoblasts were treated during 7 dayswith CS at 100 mg/ml and
with IL-1b (1 or 10 ng/ml) for the latest 24 h. CS did not signiﬁcantly
alter the basal levels of OPG. Moreover, stimulation with IL-1b at 1
or 10 ng/ml for 24 h, not modiﬁed signiﬁcantly the basal level of
OPG gene expression. However, pretreatment with CS for 7 days
before the IL-1b treatment at 1 or 10 ng/ml, increased signiﬁcantlyregulation of OPG mRNA induced by a 24-h incubation with IL-1b
by 41% and 44% of increase respectively [P< 0.001] [Fig. 5(A)].
Stimulation with IL-1b at 1 or 10 ng/ml for 24 h, increased
signiﬁcantly the basal level of RANKL gene expression. Interest-
ingly, pretreatment with CS for 7 days before the IL-1b treatment at
10 ng/ml, decreased signiﬁcantly regulation of RANKL mRNA
induced by a 24-h incubation with IL-1b by 84% of decrease
[P< 0.001] [Fig. 5(B)].
Then, the OPG/RANKL ratio was determined and data showed
[Fig. 5(C)] that, under basal condition, the expression ratio of OPG/
RANKL was signiﬁcantly increased by 35.7% when cells were
incubated with CS for 7 days. Moreover, as expected, stimulation
with IL-1b at 1 or 10 ng/ml for 24 h, decreased signiﬁcantly the
basal expression ratio of OPG/RANKL. Interestingly, pretreatment
with CS for 7 days before the IL-1b treatment at 1 or 10 ng/ml,
increased signiﬁcantly expression ratio of OPG/RANKL induced by
a 24-h incubationwith IL-1b by 63% and 91% of increase [P< 0.001]
[Fig. 5(C)].
Discussion
OA is now considered as a global organ failure involving all the
tissues of the joint1. In the last 5 years, many studies have focused
their attention on the role of the subchondral bone in the
Fig. 5. Effect of CS on IL-1b-induced OPG, RANKL gene expression and OPG/RANKL ratio. Osteoblasts were treated for 7 days in the presence or absence of CS (100 mg/ml). IL-1b (1 or
10 ng/ml) was added for the latest 24 h. Total RNA was extracted and used in quantitative PCR to determine steady-state mRNA levels of OPG (A), RANKL (B), and OPG/RANKL ratio
(C). Values are the mean with 95% CI of three independent experiments with n¼ 1/group/experiment (corrected P-values: ***P< 0.001).
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demonstrates accelerated phases of bone resorption and bone
formation27e29. These changes are associated with an altered
metabolism of osteoblasts which lead to an abnormal production of
soluble mediators. These mediators produced by bone cells can
affect deep zone chondrocytes by going through the bone-cartilage
interface30. Thus, it makes sense to target subchondral bone cells to
treat OA in order to decrease cartilage degradation.
In order to assess the role of subchondral bone osteoblasts in the
OA process we recently developed a new model of mouse osteo-
blasts in culture14. After 3 weeks of culture, cells formed a 3D
membrane, showing a strong alkaline phosphatase activity and
expressed genes characteristics of the osteoblastic phenotype
[RUNX-2, COL1A1, Bone sialoprotein (BSP), osteopontin (OPN),
osteocalcin (OC)]31. This model is accurate to assess the role of
subchondral osteoblasts in OA14.
The aim of the present study was to investigate whether CS,
a natural compound widely used in the treatment of OA symptoms,
could counteract the production of mediators known to be dele-
terious for cartilage, by murine osteoblasts in an inﬂammatory
context. We used 100 mg/ml of CS in our study. The choice of
“physiological” dose was recently discussed32. A large range of CS
concentrations have been used (i.e., 12.5e2000 mg/ml) in in vitro
studies and most of them employed about 100e200 mg/ml. These
CS concentrations are attainable in articular tissues in vivo. Phar-
macokinetic studies performed on humans and experimental
animals after oral administration of CS revealed that it can be
absorbed orally33e35, and a high content of labeled CS was found in
the synovial ﬂuid and cartilage34,35. Such concentrations for in vitro
studies are required because the treatment with CS is characterized
by a slow onset of action, with a maximal clinical effect being
attained after several months (3e6 months) of treatment. CS waschosen not only because of its well-known anti-inﬂammatory and
anti-degradative in vitro properties in cartilage but also because of
recent studies demonstrating interesting effects on subchondral
bone marrow lesions (BML)36 and on the pro-resorptive properties
of human osteoarthritis subchondral bone osteoblasts26 under-
lining a critical role of CS in the crosstalk between cartilage and
subchondral bone in OA.
Our data show that, when CS is pre-incubated for 7 days before
IL-1b treatment, the effect of IL-1b on PGE2 production is
decreased by 86% of inhibition in mouse osteoblasts. The coordi-
nate induction of COX-2 and mPGES-1 is essential for PGE2
production by osteoblasts treated by inﬂammatory stimulants.
Indeed, our results show that CS inhibits the expression of COX-2
and mPGES-1 mRNA in IL-1b-stimulated mouse osteoblasts. PGs
are considered as important local factors that modulate bone
remodeling through their effects both on osteoblasts and osteo-
clasts and have been linked to many bone-resorptive diseases37.
Among several PG produced, PGE2, a major mediator involved in
the pathogenesis of OA, is the most prominent eicosanoid in bone
tissue, mainly produced by osteoblasts6,37. PGE2 plays a multifac-
eted role in bone metabolism. This PG has indeed been shown to
stimulate osteoclastogenesis leading to bone resorption but it also
displays bone-forming activities including osteoblast formation
and differentiation37. Therefore the role of PGE2 in bone remod-
eling during OA remains controversial. In OA patients, the
production of high level of PGE2 by subchondral bone osteoblasts
is mainly associated with an anabolic and anti-resorptive pheno-
type15. Accordingly, inhibition of COX in human OA osteoblasts
restores the catabolic parathyroid hormone (PTH)-signaling
pathway to the level of control osteoblasts38. Some anabolic
processes occurring in bone during OA are responsible for the
production of an abundant osteoid matrix with abnormal features,
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review39). Therefore, due to its anabolic properties in bone, the
increase in PGE2 production could partake in this abnormal
osteoblasts activity leading to bone sclerosis and then to a wors-
ening of the OA progression. However, this potential role needs to
be clariﬁed. PGE2 is also signiﬁcantly elevated in the synovial ﬂuid
of OA patients40 and it enhances the degradative process of
proteoglycans in cartilage41. Thus, we can speculate that the
inhibition of PGE2 production by CS could decrease bone sclerosis
and could also have an anti-degradative effect in the deep zone of
OA cartilage.
PGE2 is formed from a series of enzymatic reactions involving
COXs and PGES. In an inﬂammatory context, COX-2 and mPGES-1
are induced and lead to an overproduction of PGE2. The present
ﬁndings in osteoblasts are comparable with what is seen in chon-
drocytes, that is an inhibition of both COX-2 mRNA levels and PGE2
production in presence of CS in cultured cartilage explants21.
Several transcription factors are reported to mediate the enhanced
expression of COX-2 and mPGES-1 under inﬂammatory conditions
such as nuclear factor-kappa B (NF-kB) and activator protein-1
(AP-1)42,43. Moreover, CS is involved in the formation of focal
adhesions in osteoblasts44 and earlier ﬁndings show that in oste-
ocytes and osteoblasts, c-Fos, which dimerizes with C-jun to form
the AP-1 transcription factor, is involved in the regulation of
expression of COX-2 and consequently in a reorganization of the
cytoskeleton and formation of focal adhesions45. Taken these data
together, it can be postulated that the beneﬁcial effects of CS might
be due to a speciﬁc interaction of CS with the cytoskeleton of
osteoblasts and a concomitant speciﬁc inhibition of the delayed
PGE2 release5,21,30,46.
In the present study, we demonstrate that IL-1b induces MMP-3
and MMP-13 gene expression and synthesis, and that CS is able to
signiﬁcantly counteract this effect. One possible role for MMPs is to
prepare recruitment sites for osteoclasts and its progenitors by
degrading collagenous extracellular matrix covering the mineral-
ized bone surface, and then to expose RGD (Arg-Gly-Asp)
sequences which allow osteoclasts adhesion via alpha5/beta3
integrin receptor47. Further, degradative products of collagens may
activate osteoclasts48. Thus, degradation of collagen on bone
surface does not only allow osteoclasts attachment, but may also
stimulate them to proceed to activation and resorption phases. Our
results in osteoblasts strengthen the hypothesis that CS could have
interesting properties by modulating osteoclast activation through
the inhibition of MMP-3 expression. Moreover, by decreasing the
production of MMP-3 and MMP-13 at the bone-cartilage interface
by subchondral osteoblasts, we can speculate an anti-degradative
effect of CS in the deep zone cartilage in OA49. Our results in
osteoblasts are in agreement with previous data showing that CS
down-regulated the expression of MMP-3 and MMP-13 in bovine
cartilage explants21.
Moreover, our data showing the effects of CS on the OPG and
RANKL system highlight the ability of CS to modulate osteoclast
activation. Indeed, our data revealed that CS can regulate the
expression of these molecules. When CS was pre-incubated for
7 days before IL-1b treatment, the effect of IL-1b on OPG mRNA
expression was increased by 44% and on RANKL mRNA expression
was decreased by 84% thereby CS was able to increase the mRNA
ratio of OPG/RANKL. A recent study about the use of chondroitin
and glucosamine sulfate in combination in human OA subchondral
bone osteoblasts showed the same effect of CS alone on OPG/
RANKL ratio26. OPG contains a heparin-binding domain to which
some GAGs were demonstrated to bind50. Nonetheless, it should
not be excluded that CS may also act indirectly through the
production of other factors that in turn modulate OPG/RANKL and/
or resorption activity51.Interestingly, the effect of CS on PGE2 production and MMP
expression was present only when cells were pre-incubated with
CS for a long period of time (7 days). We ﬁrst decided to select
a short period of time (24 h preincubation with CS) to test if the
effect of CS on PGE2 was due to a direct interaction between CS and
IL-1b. Indeed, a study suggested that during the immune response,
ILs tended to be retained at sites of secretion by interaction with
GAG in the extracellular matrix52. Since our data showing that 24 h
treatment of CS was not able to inhibit PGE2 production, we
considered that this hypothesis was invalidated. In addition, we
have shown that indomethacin was effective even when the pre-
incubation time was short. Such differences between an NSAID and
CSmay highlight differences in term ofmechanism of action (fast vs
long-acting effect) in OA. However, the reasons why these differ-
ences exist remain unknown yet. The mechanisms whereby CS
binds to the cell membrane and elicits intracellular signaling to play
these pleiotropic activities are quite unknown. CS is internalized in
the cell via the hyaluronan receptor for endocytosis (HARE)53, and
other scavenger receptors such as CD36 and CD4454. The mecha-
nism bywhich CS reduces p38MAPK, ERK1/2 phosphorylation, and
NF-kB nuclear translocation remains unclear but it has been re-
ported that inhibition of hyaluronan binding to CD44 by CS
diminishes ERK1/2 phosphorylation55. Since the activation of these
signaling pathways is redox-sensitive, once internalized by HARE,
the antioxidant activity of CS may have contributed to these
effects56.
In conclusion, our data demonstrate that, in an inﬂammatory
context, CS inhibits the production of PGE2 and MMPs. Since CS has
previously been shown to counteract the production of these
mediators in chondrocytes, we speculate that the beneﬁcial effect
of CS in OA could not only be due to its action on cartilage but also
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